Patrick Flume to Humans
This is a "connection" page, showing publications Patrick Flume has written about Humans.
Connection Strength
2.131
-
Inhaled nitric oxide for adults with pulmonary non-tuberculous mycobacterial infection. Respir Med. 2023 01; 206:107069.
Score: 0.032
-
A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus. J Cyst Fibros. 2022 07; 21(4):721-724.
Score: 0.030
-
C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response. J Cyst Fibros. 2022 07; 21(4):588-593.
Score: 0.030
-
The Impact of COVID-19 in Cystic Fibrosis. Arch Bronconeumol. 2022 06; 58(6):466-468.
Score: 0.030
-
Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease. Chest. 2021 12; 160(6):2042-2050.
Score: 0.029
-
Chest Computed Tomography Features of Nontuberculous Mycobacterial Pulmonary Disease Versus Asymptomatic Colonization: A Cross-sectional Cohort Study. J Thorac Imaging. 2022 May 01; 37(3):140-145.
Score: 0.029
-
Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. J Cyst Fibros. 2022 01; 21(1):96-103.
Score: 0.029
-
Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future: Adult Cystic Fibrosis Series. Chest. 2021 10; 160(4):1232-1240.
Score: 0.029
-
Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study. J Cyst Fibros. 2021 11; 20(6):1003-1009.
Score: 0.028
-
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 07; 9(7):733-746.
Score: 0.028
-
JCF Year in Review. J Cyst Fibros. 2021 01; 20(1):1-2.
Score: 0.028
-
Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment. J Cyst Fibros. 2021 03; 20(2):288-294.
Score: 0.028
-
Treatment of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2020 11; 26(6):679-684.
Score: 0.028
-
Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration Workshop. Chest. 2021 02; 159(2):537-543.
Score: 0.027
-
JCF Year in Review. J Cyst Fibros. 2020 07; 19(4):505-506.
Score: 0.027
-
Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes. Eur Respir J. 2020 04; 55(4).
Score: 0.026
-
Screening practices for nontuberculous mycobacteria at US cystic fibrosis centers. J Cyst Fibros. 2020 07; 19(4):569-574.
Score: 0.026
-
Pursuit of Equity. J Cyst Fibros. 2020 03; 19(2):171.
Score: 0.026
-
Impact of a Reduction in Susceptibility Testing for Pseudomonas aeruginosa in a Cystic Fibrosis Program. Am J Respir Crit Care Med. 2020 01 01; 201(1):114-116.
Score: 0.026
-
Cystic Fibrosis: Advances in Understanding and Treatment. Semin Respir Crit Care Med. 2019 12; 40(6):699-700.
Score: 0.026
-
Disruption in research publishing - the open access revolution. J Cyst Fibros. 2019 11; 18(6):747-749.
Score: 0.026
-
Pulmonary Complications of Cystic Fibrosis. Semin Respir Crit Care Med. 2019 12; 40(6):804-809.
Score: 0.026
-
Clinical care for cystic fibrosis: preparing for the future now. Lancet Respir Med. 2020 01; 8(1):10-12.
Score: 0.025
-
Rheumatoid arthritis-associated bronchiectasis - Authors' reply. Lancet. 2019 05 18; 393(10185):2036.
Score: 0.025
-
The study of CFTR modulators in the very young. Lancet Respir Med. 2019 04; 7(4):287-289.
Score: 0.024
-
JCF - progress in 2018. J Cyst Fibros. 2019 01; 18(1):1-5.
Score: 0.024
-
Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):737-742.
Score: 0.024
-
Optimizing outcomes of pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2018 11; 24(6):606-611.
Score: 0.024
-
Antimicrobial resistance in cystic fibrosis: Does it matter? J Cyst Fibros. 2018 11; 17(6):687-689.
Score: 0.024
-
Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018 09 08; 392(10150):880-890.
Score: 0.024
-
Mycobacterial Disease: Evolving Concepts. Semin Respir Crit Care Med. 2018 Jun; 39(3):269.
Score: 0.024
-
Nontuberculous Mycobacteria in Cystic Fibrosis. Semin Respir Crit Care Med. 2018 Jun; 39(3):383-391.
Score: 0.024
-
Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. Ann Am Thorac Soc. 2018 08; 15(8):897-902.
Score: 0.024
-
Benefits of set length antibiotic treatment for pulmonary exacerbations. Lancet Respir Med. 2018 08; 6(8):575-577.
Score: 0.023
-
Unmet needs in cystic fibrosis: the next steps in improving outcomes. Expert Rev Respir Med. 2018 07; 12(7):585-593.
Score: 0.023
-
Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis. J Genet Couns. 2018 09; 27(5):1049-1054.
Score: 0.023
-
Regulatory Support Improves Subsequent IRB Approval Rates in Studies Initially Deemed Not Ready for Review: A CTSA Institution's Experience. J Empir Res Hum Res Ethics. 2018 04; 13(2):139-144.
Score: 0.023
-
Response to Commentary: Regulatory Support Improves Subsequent IRB Approval Rates in Studies Initially Deemed Not Ready for Review-A CTSA Institution's Experience. J Empir Res Hum Res Ethics. 2018 04; 13(2):148.
Score: 0.023
-
Learning's from the Editors Desk - 2017. J Cyst Fibros. 2017 11; 16(6):645-646.
Score: 0.022
-
The Cystic Fibrosis Survival Gap: Why Do Canadians Fare Better Than Americans? Ann Intern Med. 2017 04 18; 166(8):599-600.
Score: 0.021
-
Treatment decisions for MRSA in patients with cystic fibrosis (CF): when is enough, enough? Thorax. 2017 04; 72(4):297-299.
Score: 0.021
-
Bronchodilators in cystic fibrosis: a critical analysis. Expert Rev Respir Med. 2017 01; 11(1):13-20.
Score: 0.021
-
Efficacy measures for clinical trials: A review series. J Cyst Fibros. 2016 07; 15(4):415.
Score: 0.020
-
Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):809-815.
Score: 0.020
-
Adults with cystic fibrosis in Portugal: A first step towards improvement. Rev Port Pneumol (2006). 2016 May-Jun; 22(3):139-40.
Score: 0.020
-
Aerosolized Antibiotics for Patients with Bronchiectasis. Am J Respir Crit Care Med. 2016 Apr 01; 193(7):808-10.
Score: 0.020
-
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):139-40.
Score: 0.020
-
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Cochrane Database Syst Rev. 2015 Jul 30; (7):CD009730.
Score: 0.019
-
Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis. Paediatr Respir Rev. 2015 Sep; 16(4):246-8.
Score: 0.019
-
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax. 2016 Mar; 71(3):223-9.
Score: 0.019
-
Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. J Cyst Fibros. 2015 Sep; 14(5):632-8.
Score: 0.019
-
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros. 2015 Jul; 14(4):507-14.
Score: 0.018
-
Clinical applications of pulmonary delivery of antibiotics. Adv Drug Deliv Rev. 2015 May; 85:1-6.
Score: 0.018
-
Lung clearance index. A potential quantitative tool to assess treatment response in bronchiectasis? Am J Respir Crit Care Med. 2014 Mar 01; 189(5):510-1.
Score: 0.017
-
Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring. J Cyst Fibros. 2013 Jul; 12(4):403-6.
Score: 0.016
-
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012 Sep; 142(3):718-724.
Score: 0.016
-
State of progress in treating cystic fibrosis respiratory disease. BMC Med. 2012 Aug 10; 10:88.
Score: 0.016
-
Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. Respir Med. 2011 Dec; 105 Suppl 2:S18-23.
Score: 0.015
-
Chronic cystic fibrosis respiratory infections: where do we go from here? Introduction. Respir Med. 2011 Dec; 105 Suppl 2:S1.
Score: 0.015
-
Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2011 Nov; 17(6):442-7.
Score: 0.015
-
Pneumothorax in cystic fibrosis. Curr Opin Pulm Med. 2011 Jul; 17(4):220-5.
Score: 0.014
-
Update in cystic fibrosis 2010. Am J Respir Crit Care Med. 2011 Jun 15; 183(12):1620-4.
Score: 0.014
-
Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010 Aug 01; 182(3):298-306.
Score: 0.014
-
Update in cystic fibrosis 2009. Am J Respir Crit Care Med. 2010 Mar 15; 181(6):539-44.
Score: 0.013
-
Treatment of pulmonary exacerbations in adult cystic fibrosis patients: a review. Hosp Pract (1995). 2010 Feb; 38(1):26-34.
Score: 0.013
-
Smoothing the transition from pediatric to adult care: lessons learned. Curr Opin Pulm Med. 2009 Nov; 15(6):611-4.
Score: 0.013
-
The clinical approach to lung disease in patients with cystic fibrosis. Semin Respir Crit Care Med. 2009 Oct; 30(5):505-13.
Score: 0.013
-
Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med. 2009 Nov 01; 180(9):802-8.
Score: 0.013
-
Patient-reported pain and impaired sleep quality in adult patients with cystic fibrosis. J Cyst Fibros. 2009 Sep; 8(5):321-5.
Score: 0.013
-
Airway-clearance therapy guidelines and implementation. Respir Care. 2009 Jun; 54(6):733-50; discussion 751-3.
Score: 0.012
-
Pulmonary complications of cystic fibrosis. Respir Care. 2009 May; 54(5):618-27.
Score: 0.012
-
Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009 Apr; 54(4):522-37.
Score: 0.012
-
Making the diagnosis of cystic fibrosis. Am J Med Sci. 2008 Jan; 335(1):51-4.
Score: 0.011
-
Pulmonary complications in adult patients with cystic fibrosis. Am J Med Sci. 2008 Jan; 335(1):55-9.
Score: 0.011
-
Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):957-69.
Score: 0.011
-
Impact of lung transplantation on site of death in cystic fibrosis. J Cyst Fibros. 2007 Nov 30; 6(6):391-5.
Score: 0.011
-
Pneumothorax in cystic fibrosis. Chest. 2005 Aug; 128(2):720-8.
Score: 0.010
-
Massive hemoptysis in cystic fibrosis. Chest. 2005 Aug; 128(2):729-38.
Score: 0.010
-
Emergency preparedness for the chronically ill. Am J Nurs. 2005 Mar; 105(3):68-72.
Score: 0.009
-
An unusual presentation of cystic fibrosis in an adult. Am J Kidney Dis. 2005 Mar; 45(3):e41-4.
Score: 0.009
-
Testing two different doses of tiotropium Respimat? in cystic fibrosis: phase 2 randomized trial results. PLoS One. 2014; 9(9):e106195.
Score: 0.009
-
Transition programs in cystic fibrosis centers: perceptions of team members. Pediatr Pulmonol. 2004 Jan; 37(1):4-7.
Score: 0.009
-
Pneumothorax in cystic fibrosis. Chest. 2003 Jan; 123(1):217-21.
Score: 0.008
-
Medicinal treatment of intractable dyspnea in terminally ill patients. J S C Med Assoc. 2002 Aug; 98(4):196-9.
Score: 0.008
-
Telehealth and CFTR modulators: Accelerating innovative models of cystic fibrosis care. J Cyst Fibros. 2023 Jan; 22(1):9-16.
Score: 0.008
-
Abdominal Surgical Procedures in Adult Patients With Cystic Fibrosis: What Are the Risks? Dis Colon Rectum. 2022 08 01; 65(8):e805-e815.
Score: 0.008
-
A "story" of a woman with cystic fibrosis. Chest. 2002 May; 121(5):1704-7.
Score: 0.008
-
Antipseudomonal treatment decisions during CF exacerbation management. J Cyst Fibros. 2022 09; 21(5):753-758.
Score: 0.008
-
Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry. J Cyst Fibros. 2022 09; 21(5):777-783.
Score: 0.008
-
Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. J Cyst Fibros. 2022 07; 21(4):594-599.
Score: 0.008
-
Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion. BMC Infect Dis. 2022 Mar 12; 22(1):246.
Score: 0.008
-
The rationale for aerosolized antibiotics. Pharmacotherapy. 2002 Mar; 22(3 Pt 2):71S-79S.
Score: 0.008
-
Treatment options for cystic fibrosis: case study and panel discussion. Pharmacotherapy. 2002 Mar; 22(3 Pt 2):86S-87S.
Score: 0.008
-
Improvements in anthropometric measures and gastrointestinal tolerance in patients with cystic fibrosis by using a digestive enzyme cartridge with overnight enteral nutrition. Nutr Clin Pract. 2022 Apr; 37(2):344-350.
Score: 0.008
-
A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. Am J Respir Crit Care Med. 2021 12 01; 204(11):1295-1305.
Score: 0.007
-
Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation. J Cyst Fibros. 2022 07; 21(4):574-580.
Score: 0.007
-
Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiol. 2021 09; 16:1087-1104.
Score: 0.007
-
Alterations of lipid metabolism provide serologic biomarkers for the detection of asymptomatic versus symptomatic COVID-19 patients. Sci Rep. 2021 07 09; 11(1):14232.
Score: 0.007
-
Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial. Ann Am Thorac Soc. 2021 07; 18(7):1147-1157.
Score: 0.007
-
Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease: Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure. Chest. 2021 09; 160(3):831-842.
Score: 0.007
-
Voice and Respiratory Characteristics of Men and Women Seeking Treatment for Presbyphonia. J Voice. 2022 Sep; 36(5):673-684.
Score: 0.007
-
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. J Cyst Fibros. 2021 01; 20(1):78-85.
Score: 0.007
-
Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment. J Cyst Fibros. 2021 01; 20(1):36-38.
Score: 0.007
-
Respiratory Muscle Strength Training to Improve Vocal Function in Patients with Presbyphonia. J Voice. 2022 May; 36(3):344-360.
Score: 0.007
-
The Impact of Respiratory Function on Voice in Patients with Presbyphonia. J Voice. 2022 Mar; 36(2):256-271.
Score: 0.007
-
Antimicrobial resistance: Concerns of healthcare providers and people with CF. J Cyst Fibros. 2021 05; 20(3):407-412.
Score: 0.007
-
Building global development strategies for cf therapeutics during a transitional cftr modulator era. J Cyst Fibros. 2020 09; 19(5):677-687.
Score: 0.007
-
Seven P's of publication practices. J Cyst Fibros. 2020 05; 19(3):333-335.
Score: 0.007
-
Complications of cystic fibrosis in adults. J S C Med Assoc. 2000 Mar; 96(3):112-7.
Score: 0.007
-
Finding the relevance of antimicrobial stewardship for cystic fibrosis. J Cyst Fibros. 2020 07; 19(4):511-520.
Score: 0.007
-
Is bronchiectasis really a disease? Eur Respir Rev. 2020 Mar 31; 29(155).
Score: 0.007
-
Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. J Cyst Fibros. 2020 05; 19(3):370-375.
Score: 0.006
-
Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clin Infect Dis. 2019 10 30; 69(10):1812-1816.
Score: 0.006
-
Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2020 05; 19(3):407-414.
Score: 0.006
-
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713.
Score: 0.006
-
Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. Ann Am Thorac Soc. 2019 05; 16(5):534-539.
Score: 0.006
-
Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. J Cyst Fibros. 2019 03; 18(2):236-243.
Score: 0.006
-
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018 12 15; 198(12):1559-1569.
Score: 0.006
-
Defining antimicrobial resistance in cystic fibrosis. J Cyst Fibros. 2018 11; 17(6):696-704.
Score: 0.006
-
"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis. J Clin Microbiol. 2018 09; 56(9).
Score: 0.006
-
Cystic fibrosis: when to consider lung transplantation? Chest. 1998 May; 113(5):1159-61.
Score: 0.006
-
ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018 03; 17(2):153-178.
Score: 0.006
-
Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. Contemp Clin Trials. 2018 01; 64:35-40.
Score: 0.006
-
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 01; 17(1):83-88.
Score: 0.005
-
Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017 06; 49(6).
Score: 0.005
-
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros. 2017 Sep; 16(5):600-606.
Score: 0.005
-
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2017 Sep; 16(5):592-599.
Score: 0.005
-
Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis. J Cyst Fibros. 2017 09; 16(5):607-615.
Score: 0.005
-
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. Am J Respir Crit Care Med. 2017 03 15; 195(6):814-823.
Score: 0.005
-
Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379.
Score: 0.005
-
The challenges of maintaining momentum in CF drug development and approval - Commentary. J Cyst Fibros. 2017 03; 16(2):170-171.
Score: 0.005
-
Current strategies for the long-term assessment, monitoring, and management of cystic fibrosis patients treated with CFTR modulator therapy. J Cyst Fibros. 2017 01; 16(1):163-164.
Score: 0.005
-
Current and novel therapies for cystic fibrosis. J S C Med Assoc. 1996 Sep; 92(9):381-8.
Score: 0.005
-
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. J Cyst Fibros. 2016 11; 15(6):783-790.
Score: 0.005
-
Relief of the 'air hunger' of breathholding. A role for pulmonary stretch receptors. Respir Physiol. 1996 Mar; 103(3):221-32.
Score: 0.005
-
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J Cyst Fibros. 2016 09; 15(5):634-40.
Score: 0.005
-
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. J Cyst Fibros. 2016 07; 15(4):495-502.
Score: 0.005
-
One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol. 2016 Apr; 51(4):372-8.
Score: 0.005
-
Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. J Pediatr. 2016 Feb; 169:116-21.e2.
Score: 0.005
-
Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. J Pediatr. 2015 Nov; 167(5):1081-8.e1.
Score: 0.005
-
Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros. 2016 Mar; 15(2):227-33.
Score: 0.005
-
Relief of distress of breathholding: separate effects of expiration and inspiration. Respir Physiol. 1995 Jul; 101(1):41-6.
Score: 0.005
-
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med. 2015 Jul; 3(7):524-33.
Score: 0.005
-
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 07 16; 373(3):220-31.
Score: 0.005
-
Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med. 2014 Sep; 2(9):738-49.
Score: 0.004
-
A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. Chest. 2014 Aug; 146(2):437-448.
Score: 0.004
-
Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994 Jun; 149(6):1601-7.
Score: 0.004
-
European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros. 2014 May; 13 Suppl 1:S23-42.
Score: 0.004
-
Lung transplantation for mechanically ventilated patients. J Heart Lung Transplant. 1994 Jan-Feb; 13(1 Pt 1):15-21; discussion 22-3.
Score: 0.004
-
The Fowler breathholding study revisited: continuous rating of respiratory sensation. Respir Physiol. 1994 Jan; 95(1):53-66.
Score: 0.004
-
Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros. 2013 Jul; 12(4):367-76.
Score: 0.004
-
Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012 Dec; 11(6):461-79.
Score: 0.004
-
Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med. 2012 Mar 15; 185(6):645-52.
Score: 0.004
-
Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? Respir Med. 2011 Dec; 105 Suppl 2:S9-17.
Score: 0.004
-
Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother. 2011 Jun; 55(6):2636-40.
Score: 0.004
-
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2011 Jun 01; 183(11):1510-6.
Score: 0.004
-
Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011 Jan; 10(1):54-61.
Score: 0.003
-
Cost-effective airway cultures in the cystic fibrosis patient. Am J Otolaryngol. 2009 May-Jun; 30(3):150-2.
Score: 0.003
-
The delta F508 mutation in cystic fibrosis and impact on sinus development. Am J Rhinol. 2007 Jan-Feb; 21(1):122-7.
Score: 0.003
-
Superior vena cava syndrome related to indwelling intravenous catheters in patients with cystic fibrosis. Pediatr Pulmonol. 2006 Jul; 41(7):683-7.
Score: 0.003
-
Detection of an apparent homozygous 3120G>A cystic fibrosis mutation on a routine carrier screen. J Mol Diagn. 2006 Feb; 8(1):137-40.
Score: 0.002
-
Mutations in the beta-subunit of the epithelial Na+ channel in patients with a cystic fibrosis-like syndrome. Hum Mol Genet. 2005 Nov 15; 14(22):3493-8.
Score: 0.002
-
Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care. 2004 Dec; 49(12):1504-8.
Score: 0.002
-
Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother. 2004 Jan; 48(1):281-4.
Score: 0.002
-
Wegener's granulomatosis in patients with rheumatoid arthritis. J Rheumatol. 2003 Sep; 30(9):2064-9.
Score: 0.002
-
Caring for the dying patient with lung cancer. Chest. 2002 Sep; 122(3):1028-36.
Score: 0.002
-
Pulmonary complications after esophagectomy. Ann Thorac Surg. 2002 Mar; 73(3):922-6.
Score: 0.002
-
Hepatopulmonary syndrome occurring after orthotopic liver transplantation. Liver Transpl. 2001 Dec; 7(12):1081-4.
Score: 0.002
-
Psychological functioning of adults with cystic fibrosis. Chest. 2001 Apr; 119(4):1079-84.
Score: 0.002
-
Effect of pulmonary rehabilitation on quality of life in patients with COPD: the use of SF-36 summary scores as outcomes measures. J Cardiopulm Rehabil. 2000 Jul-Aug; 20(4):231-4.
Score: 0.002
-
A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy. 1999 May; 19(5):620-6.
Score: 0.002
-
In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 1997 Sep; 41(9):2053-6.
Score: 0.001
-
The MUSC lung transplantation program: the first year's experience. J S C Med Assoc. 1995 May; 91(5):223-7.
Score: 0.001
-
Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med. 1994 Oct 13; 331(15):981-7.
Score: 0.001